This document provides the patient information leaflet for Stivarga (Regorafenib) 40mg tablets, detailing indications, dosage instructions, side effects…
The document is a Chinese language package insert for Regorafenib Tablets, marketed under the brand name Stivarga. It outlines the drug's usage for treating metastatic colorectal cancer (mCRC), gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) in patients who have previously received specific therapies.
Key sections include detailed dosage recommendations of 160mg daily, administration instructions requiring a low-fat breakfast, and extensive guidance on dose adjustments for adverse reactions such as hand-foot skin reaction (HFSR) and liver toxicity. The text also lists common side effects like pain, fatigue, diarrhea, and hypertension based on clinical trial data. This manual is written in Chinese.
The recommended dose is 160mg (4 tablets) once daily, taken orally on days 1-21 of a 28-day cycle.
The tablet should be swallowed whole with water immediately after a low-fat breakfast (30% fat content) at the same time each day.